Abstract

The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 37/08 - Antiallergic agents

Abstract

The present invention provides portable devices and systems for electrofocused blow spinning, and methods for using the same. The devices of the invention are convenient to carry and use and are able to acrodynamically spin a variety of materials in a mobile setting.

IPC Classes  ?

• D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
• D01D 5/00 - Formation of filaments, threads, or the like
• D01D 5/14 - Stretch-spinning methods with flowing liquid stretching media
• D01F 1/10 - Other agents for modifying properties

Abstract

The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 9/10 - Transferases (2.)
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides a composition comprising a Ferritin-metal nanoparticle bioconjugate, wherein the Ferritin-metal nanoparticle bioconjugate comprises at least one metal nanoparticle and at least one Ferritin or a variant or a fragment thereof conjugated to the at least one metal nanoparticle; and wherein the Ferritin-metal nanoparticle bioconjugate specifically targets at least one cell expressing a transferrin receptor 1 (TfR1), and methods of making and use thereof.

IPC Classes  ?

• A61K 33/26 - Iron; Compounds thereof
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61N 5/06 - Radiation therapy using light
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

IPC Classes  ?

• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
• C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compositions that target microglia-related diseases such as infectious diseases (e.g. HIV), neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, Huntington's diseases), neurodevelopmental disorders (e.g. autism, intellectual disability) and CNS injury (e.g. TBI, SCI), include gene editing complexes. Novel AAV-BM serotypes that can cross the blood-brain barrier and transduce microglia, and package nucleic acid sequences, inclusive of, gene-editing complexes, shRNAs, sgRNAs, miRNAs and lncRNAs are utilized in the treatment of neurological diseases.

Abstract

The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 35/00 - Antineoplastic agents

Abstract

A 2D image sensor system for optical measurements of physiological parameters through a patient's skin using spatially resolved diffuse reflectance. The system includes a 2D image sensor adapted to be placed near/against the skin with at least three wavelength-dependent spectral channels and a field of view (FOV) with multiple spatial regions of interest (ROI). A source directs light onto the skin at a distance offset from the FOV. A detector receives light reflected from the skin and collects a 2D map of the entire reflectance spatial decay profile characteristic of the skin in different detector channels. A selector identifies multiple ROI that can be uniquely positioned in each spectral channel and/or partially overlapping in the 2D reflectance spatial decay map as the elements of a multivariate regression model to approximate a physiological parameter. The increased dimensionality of the system outputs improves measurement accuracy and reduces bias in confounding optical factors.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
• G01J 3/02 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours - Details
• G01J 3/42 - Absorption spectrometry; Double-beam spectrometry; Flicker spectrometry; Reflection spectrometry
• G01N 21/49 - Scattering, i.e. diffuse reflection within a body or fluid

Abstract

Compositions include CRISPR-associated endonuclease, and one or more isolated nucleic acid sequences encoding gRNAs, wherein each gRNA is complementary to a target sequence in a retroviral genome. At least one endonuclease targets a Mannosyl Oligosaccharide Glucosidase (MOGS).

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/73 - CD4
• C07K 14/735 - Fc receptors
• C12N 5/0786 - Monocytes; Macrophages

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention provides an endoluminal medication delivery device and method configured to allow immediate, repeated, precise, and controlled circumferential medication delivery to the interface between the device and the compressed surrounding tissue lining the lumen (e.g., Mucosa/mucous membrane).

IPC Classes  ?

• A61M 25/10 - Balloon catheters

Abstract

A method of inhibiting the development of osteoclasts in patients having multiple myeloma comprising administering to a patient having multiple myeloma a therapeutically effective amount of N-Methyl-dichloropropionaniline (i.e. also known as ELP-004) for inhibiting the development of osteoclasts. The method includes wherein said N-Methyl-dichloropropionaniline is administered to said patient in a pharmaceutically acceptable vehicle.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/69 - Boron compounds
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to compositions and methods for the inhibition of the infectivity of a herpesvirus. The present disclosure relates in general to compositions and methods of treating or eradicating Herpes Simplex virus infections. The disclosure relates in particular to targeting of Herpes Simplex virus genes by gene editing complexes.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors

Abstract

Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/12 - Ketones
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - Cellulose; Derivatives thereof
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Abstract

222 coating on a surface. The invention also includes methods of preventing bacterial contamination on a surface by applying the specified coating.

IPC Classes  ?

• C09D 5/14 - Paints containing biocides, e.g. fungicides, insecticides or pesticides
• C09D 5/16 - Anti-fouling paints; Underwater paints
• C11D 3/39 - Organic or inorganic per-compounds
• A61L 31/08 - Materials for coatings

Abstract

Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present disclosure describes methods of treating a condition comprising administering a pharmaceutical composition comprising at least one short chain fatty acid (SCFA). The disclosed methods can be used to treat a skin disorder or an autoimmune disorder.

IPC Classes  ?

• A61P 17/06 - Antipsoriatics
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

A novel method of synthesizing polyacrylic beads, comprising the steps of suspending a monomer and a cross-linking agent in a solution, heating the solution in a microwave reactor, cooling the solution, and collecting the polyacrylic beads. The polyacrylic beads can be used in to remove solutes from various solutions, including blood, porcine blood, dialysate, serum, contaminated water, wastewater, and combinations thereof.

IPC Classes  ?

• B01J 13/14 - Polymerisation, crosslinking
• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
• C08F 2/46 - Polymerisation initiated by wave energy or particle radiation
• C08F 212/36 - Divinylbenzene
• C08F 220/06 - Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• C08J 3/28 - Treatment by wave energy or particle radiation
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61P 13/00 - Drugs for disorders of the urinary system
• C08F 8/42 - Introducing metal atoms or metal-containing groups
• C08J 3/07 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from polymer solutions

Abstract

A device for capturing pollution particles from a fluid is disclosed. The device includes a chamber defining a fluid pathway through which the fluid travels from an inlet, through an interior, and toward. A filter is positioned within the interior of the chamber. The filter includes one or more pairs of flat metal electrodes positioned opposite one another, and the opposed pair of electrodes form at least one channel in the fluid pathway such that a non-laminar flow of fluid having pollution particles which move adjacent to the electrodes flows from a first end of the at least one channel to a second end of the at least one channel. A power source is coupled to the filter and produces an electric field oriented perpendicular to a direction of the non-laminar flow of fluid. The electric field has a strength sufficient to polarize pollution particles in the fluid.

IPC Classes  ?

• B03C 3/09 - Plant or installations having external electricity supply dry type characterised by presence of stationary flat electrodes arranged with their flat surfaces at right angles to the gas stream
• F24F 8/192 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering by electrical means, e.g. by applying electrostatic fields or high voltages
• B01D 46/10 - Particle separators, e.g. dust precipitators, using filter plates, sheets or pads having plane surfaces
• B01D 46/24 - Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
• B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
• B03C 3/34 - Constructional details or accessories or operation thereof
• B03C 3/38 - Particle charging or ionising stations, e.g. using electric discharge, radioactive radiation or flames
• B03C 3/40 - Electrode constructions

Abstract

An artificial intelligence (Al)-based method for textual identification and feature generation. The method includes: defining a scope including type, time, and geographic dimensions of texts to be analyzed; collecting, identifying, and coding using a coding protocol selected features of the texts using a pre-defined research procedure and feature set; creating a corpus of machine-readable data and metadata in a software database that includes a scraping tool for searching the worldwide web for text instances and a corpus of text types; interfacing with the software to train an Al assist tool and validate its results; and using the Al assist tool to identify the particular text type and apply the coding protocol to create new and update existing data and metadata. Also provided are a related system and at least one computer-readable non-transitory storage media embodying software.

IPC Classes  ?

• G06F 40/20 - Natural language analysis
• G06F 40/40 - Processing or translation of natural language
• G06N 3/08 - Learning methods
• G06N 20/00 - Machine learning

Abstract

An artificial intelligence (AI)-based method for textual identification and feature generation. The method includes: defining a scope including type, time, and geographic dimensions of texts to be analyzed; collecting, identifying, and coding using a coding protocol selected features of the texts using a pre-defined research procedure and feature set; creating a corpus of machine-readable data and metadata in a software database that includes a scraping tool for searching the worldwide web for text instances and a corpus of text types; interfacing with the software to train an AI assist tool and validate its results; and using the AI assist tool to identify the particular text type and apply the coding protocol to create new and update existing data and metadata. Also provided are a related system and at least one computer-readable non-transitory storage media embodying software.

IPC Classes  ?

• G06F 40/12 - Use of codes for handling textual entities
• G06Q 50/18 - Legal services; Handling legal documents

Abstract

The present invention generally relates to engineered adeno-associated viral (AAV) vectors capable of traversing the blood-brain barrier and transducing specific neural cells with high efficiency. The present invention also relates to methods of producing engineered AAV vectors and treating diseases and disorders associated with neural cell damage and degeneration.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

The invention relates to compositions and methods that include short chain fatty acids (SCFAs), such as various butyrate and acetate, in combination with an antioxidant, such as Vitamin E, for the treatment or prevention of liver diseases or disorders, such as a nonalcoholic fatty liver disease (NAFLD), nonalcoholic sieatohepatitis (NASH), fibrosis, and other similar diseases or disorders.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• A61K 31/4738 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems

Abstract

A sound barrier device, comprising: a first panel having a plurality of perforations; a second panel with no perforations; and a connector connecting the first and second panels and forming an air gap between the first and second panels. The air gap may be formed by attaching the first and second panels to one or more frames, or by placing spacers between the first and second panels.

IPC Classes  ?

• E04B 1/82 - Heat, sound or noise insulation, absorption, or reflection; Other building methods affording favourable thermal or acoustical conditions, e.g. accumulating of heat within walls specifically with respect to sound only
• B32B 3/12 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a layer of regularly-arranged cells whether integral or formed individually or by conjunction of separate strips, e.g. honeycomb structure
• E04B 1/84 - Sound-absorbing elements

Goods & Services

Providing a website featuring information in the fields of music education, music composition, and community arts

Goods & Services

Providing a website featuring information in the fields of music education, music composition, and community arts

Abstract

A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

A method of fabricating a polymer composite material by mixing a polymer material with a planar material, depositing the mixture on a substrate, and stretching the resulting thin film, is described. Polymer composite materials produced using said method and ballistic resistant materials comprising said polymer composite materials are also described.

IPC Classes  ?

• C08K 3/38 - Boron-containing compounds
• B29B 7/90 - Fillers or reinforcements
• B29C 41/00 - Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
• B29C 55/00 - Shaping by stretching, e.g. drawing through a die; Apparatus therefor
• B29C 55/04 - Shaping by stretching, e.g. drawing through a die; Apparatus therefor of plates or sheets uniaxial, e.g. oblique
• B29C 55/18 - Shaping by stretching, e.g. drawing through a die; Apparatus therefor of plates or sheets by squeezing between surfaces, e.g. rollers
• C08F 110/02 - Ethene
• C08J 3/21 - Compounding polymers with additives, e.g. colouring in the presence of a liquid phase the polymer being premixed with a liquid phase
• C08K 7/00 - Use of ingredients characterised by shape
• F41H 5/04 - Plate construction composed of more than one layer

Abstract

An intravenous needle insertion device is described. The device includes a body having a front end, a back end, a bottom surface and a top surface sloping downward toward the front end. The device further includes a vein trough recessed within the bottom surface of the body, a needle trough recessed within the top surface of the body, a puncture window at the front end of the body, where the vein trough and the needle trough both lead into the puncture window.

IPC Classes  ?

• A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
• A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles

Abstract

Heart failure WITH Preserved Ejection Fraction (HFpEF) effects approximately three million people in the United States.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C12N 15/864 - Parvoviral vectors
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Apparatus for increasing burning efficiency including a bottom shell having a plate defining a first opening for receiving a fuel source and a side wall extending in an upward direction. The side wall has a first side wall end coupled to the plate and a second side wall end spaced from the first side wall end in the upward direction. Additionally, the apparatus includes a top shell having inner and outer walls defining a cavity for receiving the second side wall end of the side wall of the bottom shell. The inner wall has a first inner end and a second inner end and the outer wall has a first outer end and a second outer end. The first inner end is coupled to the first outer end and the second inner end is spaced from the second outer end to receive at least the second side wall end.

IPC Classes  ?

• F23D 14/06 - Premix gas burners, i.e. in which gaseous fuel is mixed with combustion air upstream of the combustion zone induction type, e.g. Bunsen burner with radial outlets at the burner head
• F23D 14/58 - Nozzles characterised by the shape or arrangement of the outlet or outlets from the nozzle, e.g. of annular configuration

Abstract

Described herein is a composition comprising porous particles, wherein the porous particles comprise an organic polymer and further comprise functional groups that selectively and reversibly bind blood components. Also described herein is method of dispersing a medical composition in a filtration unit, the method comprising the steps of: providing a vessel comprising a medical composition: securing the vessel to a filtration unit; and depositing the composition into the filtration unit; wherein the medical composition comprises porous particles comprising at least one organic polymer; the filtration unit comprises a filtration membrane having hollow fiber pores; and the average diameter of the porous particles is larger than the hollow fiber pores of the filtration membrane. Also described herein is a method of synthesizing polymer beads.

IPC Classes  ?

• B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention comprises methods for treating diseases or disorders associated with reduced levels of Ca2+ signaling, including melanoma and other cancers.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Abstract

An infusion catheter has an elongate flexible shaft including a wall and a lumen extending between a proximal end and a distal end. The catheter also has a sealing member within the shaft lumen including a wall and a lumen. The catheter also has a slidable, retractable elongate central axis member extending through the shaft and sealing member lumens connected to an end cap. The catheter also has a plurality of eluting arms extending radially around the central axis member, including lumens fluidly connected to the shaft lumen and the distal end cap. A method for treating a thrombus is also disclosed.

IPC Classes  ?

• A61B 17/221 - Calculus gripping devices in the form of loops or baskets
• A61B 17/22 - Surgical instruments, devices or methods, e.g. tourniquets for removing obstructions in blood vessels, not otherwise provided for
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61M 25/00 - Catheters; Hollow probes
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters

Abstract

The present invention relates to the discovery that various proteins are enriched in the amniotic fluid of fetuses with open neural tube defects (NTDs). The invention includes methods for the diagnosis of open NTD based upon the levels and /or differential patterns of neurocan and phosphacan in a sample of the amniotic fluid or other bodily fluid of a subject.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C07K 1/36 - Extraction; Separation; Purification by a combination of two or more processes of different types
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 38/00 - Medicinal preparations containing peptides

Goods & Services

Medical training and teaching Medical research services Surgery; Health care; Hospital services; Medical clinics; Medical services; Physician services

Abstract

The present disclosure describes compositions and methods for treating hepatitis B virus-associated hepatocellular carcinoma. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters the expression of host genes and the activity of multiple signal transduction pathways. Short chain fatty acids can be used to delay or block the progression of chronic liver disease to HCC by targeting functions associated with HBx.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 35/00 - Antineoplastic agents
• A61K 33/08 - Oxides; Hydroxides

Abstract

Compositions for prevention or treatment for the SARS family of coronaviruses, e.g., SARS-CoV-2 and SARS-OC43 (common cold virus), include non-nucleoside reverse transcriptase inhibitors (NNRTI), such as rilpivirine, and nucleoside-analogue antiviral agents, such as remdesivir.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed herein are methods and pharmaceutical compositions to treat systemic inflammatory response syndrome. In some embodiments, a pharmaceutical composition disclosed herein comprises at least two short chain fatty acids or pharmaceutically-acceptable salts thereof in a ratio of at least 4:1. In some embodiments, administering a pharmaceutical composition of the disclosure reduces a level of a cytokine in the subject.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 47/38 - Cellulose; Derivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention generally relates to improved methods for characterizing the cell wall complex composition of a bacterial specimen via differential transport kinetics of a small molecule. The present invention also relates to improved and automated methods for Gram differentiation of a bacterial specimen using nonlinear optical techniques.

IPC Classes  ?

• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited

Abstract

Anion antisite defects in monolayer Transition Metal Dichalcogenide (TMD) systems are here identified as two-dimen-sional solid-state defect qubits. The proposed antisites in these TMDs host paramagnetic triplet ground states with flexible level splitting. A viable transition loop between the triplet and singlet defect states is demonstrated, including optical excitations/relaxations and nonradiative decay paths for the antisites as qubits. A complete set of qubit operational processes, including initialization, manipulation, and readout, is delineated.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• H01L 29/66 - Types of semiconductor device

Abstract

The invention provides methods of treating ischemia/reperfusion injury in a subject. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide in ischemic tissue. The invention also provides methods of treating a subject at risk of ischemia/reperfusion injury. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide. In the invention methods, in one example, a pharmaceutical composition comprises a nucleic acid encoding BAG3 polypeptide.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 31/69 - Boron compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/05 - Dipeptides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Compositions include gene editing agents, e.g. CRISPR that employ Cas13a for editing and inactivating sequences in the Coronavirus genome.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides porous biomimetic scaffolds and methods for making the same. The scaffolds have graded pore sizes for enhanced cell penetration. The scaffolds are useful for wound regeneration by facilitating cell penetration into the scaffold interior and due to their inherent immunomodulatory effects. The scaffolds have tissue modeling specification by mimicking the inherent stratified structure of certain tissues.

IPC Classes  ?

• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/56 - Porous or cellular materials
• D01D 5/00 - Formation of filaments, threads, or the like

Abstract

BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for example, complicated by Chronic Traumatic Encephalopathy (CTE). Therapeutically effective BAG3 compositions, BAG3 uses and BAG3 methods of treatment are described.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/864 - Parvoviral vectors

Abstract

A system for detecting mechanically damaged energy storage devices comprises an analyzer, a battery electrically connected to the analyzer, and a computing system communicatively connected to the analyzer and/or battery. A method for detecting mechanically damaged energy storage devices comprises applying an input at a range of frequencies to an energy storage device, measuring an output from the energy storage device, performing Electrochemical Impedance Spectroscopy (EIS) with Dynamic Relaxation Time (DRT) to calculate an impedance spectrum of the energy storage device, and modeling the energy storage device based on the impedance spectrum to identify if the energy storage device is mechanically damaged.

IPC Classes  ?

• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery

Abstract

Compositions that specifically cleave target sequences in Hepadnaviridae, for example Hepatitis B virus (HBV) include nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in HBV. These compositions are administered to a subject for eradicating an infection, latent or otherwise, or at risk for contracting HBV infection.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61P 31/20 - Antivirals for DNA viruses
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/46 - Hydrolases (3)
• C12N 9/22 - Ribonucleases

Abstract

Compositions which specifically target Human T cell leukemia virus (HTLV) coding sequences and other essential protein sequences, induce mutations and/or deletions in the viral DNA, rendering the virus unable to undergo replication and less likely to infect other cells, thus halting the viral life cycle and viral propagation and halting cellular transformation induced by the virus.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors

Abstract

The present invention provides novel intermediates and other compounds prepared using compounds of Formula I. These novel compounds include spiroligomers that have particular significance in the peptide industry. The processes described herein provide products that are produced in high yields in high purities and, thus, are highly efficient.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone

Abstract

The present invention generally relates to novel compositions and methods for regenerating damaged cardiac tissue. In some embodiments, the invention comprises activators of phosphor-serine aminotransferase (PSAT1) and methods of use thereof for the treatment of damaged cardiac tissue following myocardial infarction.

IPC Classes  ?

• C12N 15/52 - Genes encoding for enzymes or proenzymes
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 9/10 - Transferases (2.)

Abstract

Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/− had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Compositions include gene-editing complexes for the treatment of myopathies, cancer and neurodegenerative diseases. Specifically, the disclosure provides methods of identifying in a subject's biological sample, 'at least one Bcl2-associated anthanogene 3 (BAGS) genetic mutation as compared to a control BAGS nucleic acid sequence, and administering to the subject a therapeutically effective amount of a gene-editing complex, wherein the gene-editing complex corrects the bag3 mutation to a wild-type bag3, thereby, treating the subject.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 38/46 - Hydrolases (3)
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Polymer composites may be made by providing a first polymer material; treating the first polymer material; providing a second polymer material; and pressing the first polymer material and the second polymer material. The polymer composites may be incorporated into ballistic resistant materials and soft armor articles.

IPC Classes  ?

• B32B 27/12 - Layered products essentially comprising synthetic resin next to a fibrous or filamentary layer
• B32B 27/16 - Layered products essentially comprising synthetic resin specially treated, e.g. irradiated
• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
• B32B 27/34 - Layered products essentially comprising synthetic resin comprising polyamides
• B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
• C08L 23/06 - Polyethene
• C08L 77/10 - Polyamides derived from aromatically bound amino and carboxyl groups of amino carboxylic acids or of polyamines and polycarboxylic acids
• C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment

Abstract

A magnetometer-based metal detection device and methods of use are described. The device includes a proximal portion, a central body and a distal portion, and at least one magnetometer positioned within or on the distal portion. The at least one magnetometer includes at least one sensor capable of sensing a magnetic field in three orthogonal axes. Also described is a method of calibrating the device to achieve rotational invariance, and a method of determining a directionality or directional line along which a target metal object lies.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies

Abstract

Migration of HIV-1 infected monocytes across the endothelial barrier plays an essential role in establishing and maintenance of viral reservoir in the brain and leads to neuroinflammation, neuronal damage, and subsequent HIV-induced central nervous system (CNS) dysfunction. These processes continue despite antiretroviral therapy (ART) due to limited pharmacological permeability of the blood-brain barrier, the presence of residual viral replication, and the reactivation of latent viruses. Compositions comprising Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonucleases targeted to activated leukocytes cell adhesion molecule (ALCAM/CD166), chemotactic recruitment (CCR2/5), adhesion to the endothelium (ALCAM) and junctional diapedesis (JAM-A) achieves maximum repression of leukocyte transmigration and block of the spread of the virus to different tissues and organs.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

Compositions and methods are provided for Tat-inducible expression of a CRISPR-associated endonuclease by a truncated HIV LTR promoter containing at least a core region and a TAR region of a HIV LTR promoter. The compositions may be used as a therapeutic treatment for the treatment and/or prevention of HIV.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors

Abstract

A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-I proviral genome, eradicating the HIV-I proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases

Abstract

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention relates to compositions and methods to detect hybrids with high sensitivity and selectivity in order to assess cell, tissue and organism function in both health and disease. The invention described herein, termed epiprinter, is a functionally versatile molecular entity that can detect RNA-DNA hybrids with potentially high sensitivity and selectivity.

IPC Classes  ?

• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Abstract

Compositions that specifically cleave target sequences in Herpesviridae, for example Varicella zoster virus (VZV) include nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in VZV. These compositions are administered to a subject for treating an infection or at risk for contracting a VZV infection.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/46 - Hydrolases (3)
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Goods & Services

Magnets; Cell phone cases Bracelets; Clocks; Cuff links; Key chains; Pins being jewelry; Tie bars; Tie clips; Watch bands; Lapel pins Decals; Pens; Gift bags; Paper weights; Stationery-type portfolios; Blank notepads; Paper notebooks Backpacks; Umbrellas; Wallets; Briefcase-type leather business folders; Drawstring bags; Gym bags; Tote bags Mugs; Bottle openers; Drinking glasses; Water bottles sold empty Banners of textile or plastic; Blanket throws; Flags of textile or plastic Aprons; Hats; Shirts; Shorts; Sleepwear; Socks; Sweaters; Baseball caps; Infant wear; Neckties; Sweat pants; Sweat shirts; Wristbands as clothing; Clothing jackets; Sports jerseys Christmas tree ornaments and decorations; Golf balls; Stuffed toy animals

Goods & Services

Educational services, namely, providing courses of instruction at the undergraduate, graduate, and post-graduate level; Organizing and conducting college sport competitions and athletic events

Goods & Services

Magnets; Cell phone cases Bracelets; Clocks; Cuff links; Key chains; Pins being jewelry; Tie bars; Tie clips; Watch bands; Lapel pins Decals; Pens; Gift bags; Paper weights; Stationery-type portfolios; Blank notepads; Paper notebooks Backpacks; Umbrellas; Wallets; Briefcase-type leather business folders; Drawstring bags; Gym bags; Tote bags Mugs; Bottle openers; Drinking glasses; Water bottles sold empty Banners of textile or plastic; Blanket throws; Flags of textile or plastic Aprons; Hats; Shirts; Shorts; Sleepwear; Socks; Sweaters; Baseball caps; Infant wear; Neckties; Sweat pants; Sweat shirts; Wristbands as clothing; Clothing jackets; Sports jerseys Christmas tree ornaments and decorations; Golf balls; Stuffed toy animals

Goods & Services

Educational services, namely, providing courses of instruction at the undergraduate, graduate, and post-graduate level; Organizing and conducting college sport competitions and athletic events

Abstract

This invention provides compositions comprising linked amino acid sequences, pharmaceutical compositions comprising linked amino acid sequences, and methods of making thereof. This invention also provides methods of delivering said compositions to subjects and methods of treating various disorders and diseases using the said compositions.

IPC Classes  ?

• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/- had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 25/16 - Anti-Parkinson drugs
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/- had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

IPC Classes  ?

• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 493/10 - Spiro-condensed systems
• C07D 295/073 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups
• C07D 513/04 - Ortho-condensed systems

Abstract

Systems and methods are provided for a virtual network storage as a transaction pool of a transactional application. In particular, the virtual network storage includes a set of gateway servers that form unidirectional virtual ring as a virtual single-system image of an Active Content Addressable Network (AC AN). Each gateway server manages a partition of a database by driving replicated database servers, in a shifted mirror fashion. The ACAN may represent a transaction pool for processing transactions of a blockchain (e.g., crypto-currency). Unlike traditional blockchain crypto-currency protocols based on lower level hop-to-hop networking protocols, the disclosed technology processes data in parallel without addresses or hops by decoupling applications from processing hardware and networks, thereby attaining performance while maintaining scalability and reliability incrementally without infrastructure size limitations. Accordingly, the disclosed technology enables quantum-class cloud computing.

IPC Classes  ?

• G06F 21/30 - Authentication, i.e. establishing the identity or authorisation of security principals
• G06Q 40/02 - Banking, e.g. interest calculation or account maintenance

Abstract

Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

A system for distributed dual-function radar-communication comprises a plurality of dual-function radar transmitters positioned within a region of interest, each configured to transmit at least one radar waveform, with each transmitter for having a minimum transmit power, a maximum transmit power, and a working transmit power, a plurality of radar receivers positioned within the region of interest, each configured to receive the radar waveforms, at least one controller communicatively connected to at least one connected transmitter of the plurality of dual-function radar transmitters, configured to calculate a vector of transmit power values for the plurality of dual-function radar transmitters. A method of transmitting a radar waveform is also disclosed.

IPC Classes  ?

• G01S 7/00 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , ,
• G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified

Abstract

The present invention relates to compositions and methods relating to biomarkers (e.g., calcitriol (i.e., 1,25(OH)2D3) to 24,25-dihydroxyvitamin D3 (i.e., 24,25(OH)2D3) to calcifediol (i.e., 25(OH)D3) proportion ratio (C24CPR)) that can be used for detection and treatment assessment of vitamin D deficiency or vitamin D imbalance and/or diseases or disorders associated with vitamin D deficiency or vitamin D imbalance, such as cancer, in a subject in need thereof. The present invention also provides methods of diagnosing vitamin D deficiency or vitamin D imbalance and/or diseases or disorders associated with vitamin D deficiency or vitamin D imbalance and distinguishing between different types of diseases or disorders associated with vitamin D deficiency or vitamin D imbalance (e.g., cancer vs autoimmune disease or disorder).

IPC Classes  ?

• G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode

Abstract

The invention provides methods of delivering a therapeutic to the heart. In one embodiment, a method includes administering to a subject the therapeutic via retrograde coronary venous or sinus delivery thereby delivering the therapeutic to the heart.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61M 25/00 - Catheters; Hollow probes
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The invention provides methods of delivering a therapeutic to the heart. In one embodiment, a method includes administering to a subject the therapeutic via retrograde coronary venous or sinus delivery thereby delivering the therapeutic to the heart.

IPC Classes  ?

• A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• A61P 9/12 - Antihypertensives

Abstract

This invention provides unnatural amino acids as well as amino acid sequences, foldamers, macrocycles, and formulations comprising said unnatural amino acids. In one aspect of the invention, the unnatural amino acids or the formulation thereof are used to mimic natural amino acids or the formulations thereof in a subject in need thereof.

IPC Classes  ?

• C07D 487/10 - Spiro-condensed systems
• C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
• C07D 487/20 - Spiro-condensed systems
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Abstract

A mobile-platform imaging device uses compression of the target region to generate an image of an object. A tactile sensor has an optical waveguide with a flexible, transparent first layer. Light is directed into the waveguide. Light is scattered out of the first layer when the first layer is deformed. The first layer is deformed by the tactile sensor being pressed against the object. A force sensor detects a force pressing the tactile sensor against the object and outputs corresponding force information. A first communication unit receives the force information from the force sensor. A receptacle holds a mobile device with a second communication unit and an imager that can generate image information using light scattered out of the first layer. The first communication unit communicates with the second communication unit and the mobile device communicates with an external network.

IPC Classes  ?

• G02B 6/10 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 19/00 - Investigating materials by mechanical methods
• G06T 7/00 - Image analysis
• G06V 10/10 - Image acquisition
• G06V 10/147 - Optical characteristics of the device performing the acquisition or on the illumination arrangements - Details of sensors, e.g. sensor lenses
• H04M 1/04 - Supports for telephone transmitters or receivers

Abstract

The present invention generally relates to kits for detecting Mycobacterium avium subspecies paratuberculosis (MAP) infection and biomarkers correlated with MAP-associated diseases or disorders. The present method also relates to methods of diagnosing a subject with a MAP-associated autoimmune disease or disorder and/or determining the treatment course of a subject diagnosed with a MAP-associated autoimmune disease or disorder.

IPC Classes  ?

• G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease

Abstract

A novel, small (21-mer oligonucleotide) and unique cz's-regulatory coding motif can greatly enhance the production of a variety of different types of proteins ranging from viral transcripts/proteins, endogenous gene products, vaccines, antibodies to engineered recombinant proteins in mammalian cells. The combination of novel peptide tag(s) having specified short amino acid sequences or derivatives thereof and the untranslated region (UTR) of viruses (snUTR) enhanced production of tagged proteins, including viral transcripts/proteins, endogenous gene products, vaccine, antibody, engineered recombinant proteins in a cell both in vitro, ex vivo and in vivo.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

A novel, small (21-mer oligonucleotide) and unique cz's-regulatory coding motif can greatly enhance the production of a variety of different types of proteins ranging from viral transcripts/proteins, endogenous gene products, vaccines, antibodies to engineered recombinant proteins in mammalian cells. The combination of novel peptide tag(s) having specified short amino acid sequences or derivatives thereof and the untranslated region (UTR) of viruses (snUTR) enhanced production of tagged proteins, including viral transcripts/proteins, endogenous gene products, vaccine, antibody, engineered recombinant proteins in a cell both in vitro, ex vivo and in vivo.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 35/32 - Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane

Abstract

The present invention discloses a photon enhancement apparatus comprising a reflective component and 4f coherent imaging system, which increases a photon collection efficiency. The present invention also provides a microscope comprising said photon enhancement apparatus and methods of improving photon collection efficiency, signal-to-noise ratio, and/or optical resolution using the said photon enhancement apparatus.

IPC Classes  ?

• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• G02B 21/08 - Condensers
• G02B 21/16 - Microscopes adapted for ultraviolet illumination
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising an CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• A61K 38/46 - Hydrolases (3)

Abstract

Compositions include CRISPR-associated endonuclease, and one or more isolated nucleic acid sequences encoding gRNAs, wherein each gRNA is complementary to a target sequence in a retroviral genome. At least one endonuclease targets a Mannosyl Oligosaccharide Glucosidase (MOGS).

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/12 - Antivirals
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The invention relates to amphiphilic Janus dendrimers which may form nanoparticles. The invention also relates to methods of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of a composition comprising at least one nucleoside-modified RNA encoding at least one antigen and at least one amphiphilic Janus dendrimer and to methods of delivering an agent to a subject in need thereof, said method comprising the step of delivering to the subject a composition comprising an agent encapsulated by a nanoparticle.

IPC Classes  ?

• C07C 69/78 - Benzoic acid esters
• C08G 63/44 - Polyamides; Polynitriles

Abstract

Provided herein are gene editing compositions and methods that effectively modulate and/or edit a JCV genome. The effective modulation and/or editing is, in an aspect, achieved by gene editing compositions targeting a NCCR region, an early coding gene, and/or a late coding gene.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

Gene editing complexes are specifically directed to cannabinoid sequences, such as tetrahydrocannabinol (THC), for excision or inactivation of these sequences. The disclosure is directed to the inhibition of synthesis of THC in a cannabis plant. In doing so, THC would never become an active compound within the plant chemistry and chemotype, thereby eliminating the chance of CBD extracts being contaminated with THC.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

Immune Modulatory Paracrine Acting Cells (IMPACS) and uses in the prevention or treatment of cardiovascular diseases and disorders thereof.

IPC Classes  ?

• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• A61K 35/34 - Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

IPC Classes  ?

• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
• C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 307/28 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. A is selected from a group consisting of (group) and (group) Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. A is selected from a group consisting of (group) and (group)

IPC Classes  ?

• C07D 471/10 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention generally relates to engineered adeno-associated viral ( AAV) vectors capable of traversing the blood-brain barrier and transducing specific neural cells with high efficiency. The present invention also relates to methods of producing engineered AAV vectors and treating diseases and disorders associated with neural cell damage and degeneration.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

The present invention relates to methods and compositions comprising a miR-302 mimic/s for treatment of lung injury. The miRNA-302 mimic/s facilitate host recovery from lung injury caused due to, for example, bacterial pneumonia

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/04 - Antibacterial agents

Abstract

The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents

Abstract

Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 15/32 - Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
• A61L 15/44 - Medicaments
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 15/26 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61L 27/52 - Hydrogels or hydrocolloids